Diosmin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Diosmin: From Venous Disease to Amenorrhea
One-Sentence Summary
Diosmin is a flavonoid venoactive agent, widely marketed in India as a single-ingredient product for venous conditions. The TxGNN model predicts it may be effective for amenorrhea, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a purely computational signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated on the India licences (indication text is blank) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 0.9942 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (17 of 17) – CDSCO approval status is not included in this data |
| Number of Listed Products | 17 (valid: 17) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general knowledge, diosmin is a flavonoid venoactive agent used for chronic venous insufficiency and haemorrhoids. Its proposed effects are on venous tone, capillary permeability, lymphatic drainage and inflammation. These details are background knowledge and are not drawn from the data compiled for this report.
No plausible link has been identified between these actions and the hypothalamic-pituitary-ovarian axis, endometrial function, or other drivers of amenorrhea. The India licences list no approved indication text, which further limits inference. Any connection would be speculative, for example through indirect vascular or anti-inflammatory effects. The very high TxGNN score (0.9942) should therefore be read as a model output, not as biological or clinical confirmation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Diosmin has 17 valid registrations in India and no cancelled ones. Five main authorisations are listed below. The approved-indication text is blank on all of them.
Review correction (2026-11-06): Originally stated: “Diosmin has 17 valid single-ingredient registrations in India and no cancelled ones.” Removed: it described the products as single-ingredient or combination products in a way that did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-11-06). Source: Indian Medicine Dataset.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 104457 | Hesdin Tablet | Strip of 15 tablets | Not specified |
| 58244 | Daflon 500 MG Tablet | Strip of 10 tablets | Not specified |
| 58279 | Daflon 1000mg Tablet | Strip of 10 tablets | Not specified |
| 133 | Aldosmin 500mg Tablet | Strip of 10 tablets | Not specified |
| 230756 | Ubicar Cream | Tube of 30 gm cream | Not specified |
Most products are oral tablets. One topical cream (Ubicar Cream) is also registered.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no clinical trials, no literature and no plausible mechanistic link to amenorrhea. Evidence is at the lowest level (L5).
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank) to assess any biological link
- Package insert warnings and contraindications from the India licences, to allow safety screening
- A literature and trial search specifically on diosmin or flavonoids and menstrual or ovarian function
- A clear clinical rationale for amenorrhea, including the type (primary or secondary) and cause, before any further evaluation
Review Log
Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.
| Review date | Item | Action | Source |
|---|---|---|---|
| 2026-11-06 | Removed: “single-ingredient” | Corrected | Indian Medicine Dataset |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.